Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis

MLA

Satoshi Ikeda, et al. “Rationale and Protocol Design for the TORG1835/NEXT-SHIP Study: A Phase II Study of Carboplatin, Etoposide and Nintedanib for Unresectable Limited/Extensive Disease Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis.” Therapeutic Advances in Medical Oncology, vol. 12, May 2020. EBSCOhost, https://doi.org/10.1177/1758835920923431.

APA

Satoshi Ikeda, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Tae Iwasawa, Toshihiro Misumi, Takeharu Yamanaka, & Hiroaki Okamoto. (2020). Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Therapeutic Advances in Medical Oncology, 12. https://doi.org/10.1177/1758835920923431

Chicago

Satoshi Ikeda, Takashi Ogura, Terufumi Kato, Hirotsugu Kenmotsu, Tae Iwasawa, Toshihiro Misumi, Takeharu Yamanaka, and Hiroaki Okamoto. 2020. “Rationale and Protocol Design for the TORG1835/NEXT-SHIP Study: A Phase II Study of Carboplatin, Etoposide and Nintedanib for Unresectable Limited/Extensive Disease Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis.” Therapeutic Advances in Medical Oncology 12 (May). doi:10.1177/1758835920923431.